Peginterferon alfa-2a in patients with chronic hepatitis C.
暂无分享,去创建一个
J. Reichen | M. Lai | S. Zeuzem | M. Diago | E. Gane | J. O'grady | M. Brunda | S Zeuzem | E. Heathcote | M Y Lai | M J Brunda | S V Feinman | J Rasenack | E J Heathcote | E Gane | J O'Grady | J Reichen | M Diago | A Lin | J Hoffman | J. Rasenack | J. Reichen | A. Lin | S. Feinman | J. Hoffman | E. Gane | S. Zeuzem | S. Zeuzem
[1] A. Neumann,et al. Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa , 1997, Hepatology.
[2] G. Farrell,et al. Therapy of hepatitis C: Interferon alfa‐n1 trials , 1997, Hepatology.
[3] N. E. Breslow. Statistical Methods in Cancer Research , 1986 .
[4] M Gent,et al. An alternative to the use of two-sided tests in clinical trials. , 1996, Statistics in medicine.
[5] Ding‐Shinn Chen,et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. , 1996, Gastroenterology.
[6] M. Shiffman,et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. , 2000, The New England journal of medicine.
[7] J. Hoefs,et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[8] D. Mould,et al. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa‐2a and a polyethylene glycol‐modified derivative in healthy subjects , 1996, Clinical pharmacology and therapeutics.
[9] Aril Frydén,et al. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C , 1998, The Lancet.
[10] J. Schmidt,et al. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo , 1996, Hepatology.
[11] William M. Lee,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[12] Alan S. Perelson,et al. Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .
[13] R. Wills. Clinical Pharmacokinetics of Interferons , 1990, Clinical pharmacokinetics.
[14] Don Kelly. Hotel Dieu Hospital , 1910 .
[15] T. Poynard,et al. Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration , 1996, Hepatology.
[16] P. Marcellin,et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C , 1995, Hepatology.
[17] E. Shaffer,et al. Effect of the prokinetic agent, erythromycin, in the richardson ground squirrel model of cholesterol gallstone disease , 1998, Hepatology.
[18] P. Marcellin,et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.
[19] S. Emerson,et al. Therapy of hepatitis C: Meta‐analysis of interferon alfa‐2b trials , 1997, Hepatology.
[20] Neil Kaplowitz,et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.
[21] N. Breslow,et al. Statistical methods in cancer research. Vol. 1. The analysis of case-control studies. , 1981 .